Camp4 Therapeutics Corp Chief Financial Officer Kelly Gold purchased 10,000 shares of the company’s common stock on August 31, 2026, according to regulatory filings.
The transactions were executed in the open market at prices between $3.88 and $4.00 per share, with a weighted average price of $3.96. The total value of the purchase amounted to $39,600.
The shares were acquired through a brokerage account held in the name of David Gold, Kelly Gold’s spouse. In the filing, Kelly Gold stated she does not exercise investment control over the account and disclaimed beneficial ownership beyond her pecuniary interest in the shares.
Camp4 Therapeutics’ stock has shown volatility in recent weeks. Over the past seven days, the shares have declined approximately 8%, though the year-to-date gain remains substantial at roughly 170%.
The purchase follows recent analyst actions on the stock. JPMorgan upgraded Camp4 Therapeutics from Neutral to Overweight and raised its price target to $9.00 from $5.00, citing potential in the company’s CMP-002 program. Separately, Chardan initiated coverage with a Buy rating and set a price target of $6.50.
